Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

One-sample multiple testing procedure for phase II clinical trials.

Fleming TR.

Biometrics. 1982 Mar;38(1):143-51.

PMID:
7082756
2.

[Design and analysis of phase II trials in oncology with a group sequential method, the triangular test].

Bellissant E, Bénichou J, Chastang C.

Therapie. 1991 Jan-Feb;46(1):21-7. French.

PMID:
2020920
3.

Optimal and minimax three-stage designs for phase II oncology clinical trials.

Chen K, Shan M.

Contemp Clin Trials. 2008 Jan;29(1):32-41. Epub 2007 May 6.

PMID:
17544337
4.

An optimal three-stage design for phase II clinical trials.

Ensign LG, Gehan EA, Kamen DS, Thall PF.

Stat Med. 1994 Sep 15;13(17):1727-36.

PMID:
7997706
5.

An efficient multiple-stage procedure for phase II clinical trials that have high response rate objectives.

Chen S, Soong SJ, Wheeler RH.

Control Clin Trials. 1994 Aug;15(4):277-83.

PMID:
7956267
6.

The group sequential triangular test for phase II cancer clinical trials.

Bellissant E, Bénichou J, Chastang C.

Am J Clin Oncol. 1996 Aug;19(4):422-30.

PMID:
8677918
7.

Multinomial phase II cancer trials incorporating response and early progression.

Zee B, Melnychuk D, Dancey J, Eisenhauer E.

J Biopharm Stat. 1999 May;9(2):351-63.

PMID:
10379698
8.

A multiple testing procedure for clinical trials.

O'Brien PC, Fleming TR.

Biometrics. 1979 Sep;35(3):549-56.

PMID:
497341
9.

Sequential methods and group sequential designs for comparative clinical trials.

Sébille V, Bellissant E.

Fundam Clin Pharmacol. 2003 Oct;17(5):505-16. Review.

PMID:
14703713
10.
11.
12.
13.

Further results on a multiple-testing procedure for clinical trials.

Seigel D, Milton RC.

Biometrics. 1983 Dec;39(4):921-8.

PMID:
6671127
14.

The analysis of titration studies in phase III clinical trials.

Shih WJ, Gould AL, Hwang IK.

Stat Med. 1989 May;8(5):583-91.

PMID:
2727477
15.

A framework for two-stage adaptive procedures to simultaneously test non-inferiority and superiority.

Koyama T, Sampson AR, Gleser LJ.

Stat Med. 2005 Aug 30;24(16):2439-56.

PMID:
15977285
16.

Planned versus attained design in phase II clinical trials.

Green SJ, Dahlberg S.

Stat Med. 1992 May;11(7):853-62.

PMID:
1604065
17.

New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.

Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G.

Clin Cancer Res. 2005 Aug 1;11(15):5342-6.

18.

Applying sample survey methods to clinical trials data.

LaVange LM, Koch GG, Schwartz TA.

Stat Med. 2001 Sep 15-30;20(17-18):2609-23.

PMID:
11523072
19.

A predictive probability design for phase II cancer clinical trials.

Lee JJ, Liu DD.

Clin Trials. 2008;5(2):93-106. doi: 10.1177/1740774508089279.

PMID:
18375647
20.

A parallel phase I/II clinical trial design for combination therapies.

Huang X, Biswas S, Oki Y, Issa JP, Berry DA.

Biometrics. 2007 Jun;63(2):429-36.

PMID:
17688495
Items per page

Supplemental Content

Write to the Help Desk